Welcome to our dedicated page for Eastman Chem Co SEC filings (Ticker: EMN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Eastman Chemical Company (EMN) SEC filings page provides access to the company’s regulatory disclosures as a public issuer on the New York Stock Exchange. As a global specialty materials company in the plastics material and resin manufacturing industry, Eastman files periodic and current reports that describe its financial condition, results of operations, governance matters, and material events.
Among the most closely watched documents are annual reports on Form 10-K and quarterly reports on Form 10-Q, which include segment information, discussions of end-market demand in areas such as transportation, building and construction, and consumables, and commentary on topics like cash generation, cost structure, and specialty materials performance. Current reports on Form 8-K provide timely updates on specific events, including quarterly earnings releases, Board and executive changes, and other matters the company deems material.
Investors can also review proxy statements for information on Board composition, committee assignments, and director compensation, as well as filings related to executive compensation and governance. For those monitoring insider activity, Forms 3, 4, and 5 disclose transactions by directors and officers in Eastman’s common stock.
On this page, AI-powered tools summarize lengthy filings, highlight key sections, and help explain complex topics such as non-GAAP measures like adjusted EBIT and adjusted earnings per diluted share that Eastman discusses in its earnings materials. Real-time updates from the SEC’s EDGAR system ensure that new EMN filings, including 10-K, 10-Q, 8-K, and Form 4 submissions, are available quickly, allowing users to review the underlying disclosures and the AI-generated insights side by side.
Caveness Michelle H reported acquisition or exercise transactions in a Form 4 filing for EMN. The filing lists transactions totaling 1,937 shares. Following the reported transactions, holdings were 8,183 shares.
Eastman Chemical executive Brian Travis Smith acquired 10,589 shares of common stock on February 11, 2026 through a performance award. The shares were granted at a price of $0 per share following the determination of performance shares earned for the 2023–2025 period.
After this award, Smith directly beneficially owns 27,321 shares of Eastman Chemical common stock.
Eastman Chemical senior vice president Adrian James Holt received an equity award linked to company performance. On 02/11/2026, Holt acquired 2,297 shares of Eastman Chemical common stock at a price of $0 per share. These shares were granted following the determination of performance shares earned for the three-year 2023–2025 performance period, and are held as direct beneficial ownership.
Eastman Chemical Company reports 2025 full-year results and outlines its strategy as a global specialty materials company. Sales revenue reached $8.8 billion, with EBIT of $776 million, net earnings attributable to Eastman of $474 million, and diluted EPS of $4.10. Net cash from operating activities was $970 million.
The company emphasizes an innovation-driven growth model, focusing on specialty polymers, films, additives, intermediates, and fibers across four segments. It highlights molecular recycling and “Renew” branded products, with its polyester molecular recycling facility generating about 2.5 times more output than 2024. Around 55% of 2025 sales came from outside the United States and Canada.
Eastman Chemical CEO and Board Chair Mark J. Costa reported an insider equity transaction involving company stock on February 4, 2026. He exercised 48,649 employee stock options at an exercise price of $65.16 per share, receiving the same number of Eastman Chemical common shares.
A portion of these shares, 43,638, was withheld by Eastman Chemical to cover the option exercise price and tax withholding obligations in a net exercise, which the filing states does not represent a sale by Costa. After these transactions, Costa directly owned 458,997 shares of common stock, with an additional 3,231 shares held indirectly through an ESOP.
Eastman Chemical Company’s EVP and CFO, William Thomas McLain Jr., reported an option-related share transaction. On 02/04/2026 he exercised employee stock options for 3,013 shares of common stock at an exercise price of $65.16 per share.
To cover the option exercise price and tax withholding in a “net exercise,” 2,636 shares were withheld by Eastman Chemical and not sold on the market. After these transactions, he directly beneficially owned 53,901 shares of Eastman Chemical common stock.
A shareholder of EMN has filed a Rule 144 notice to sell 6,016 common shares through Fidelity Brokerage Services LLC on or about 02/04/2026, to be sold on the NYSE with an aggregate market value of $475,011.96.
The shares come from restricted stock that vested as compensation on 02/19/2021, 10/15/2022, and 02/15/2023, in amounts of 2,249, 1,040, and 2,727 shares. Shares outstanding were 114,069,800 at the time of the notice; this is a baseline figure, not the amount being sold.
Eastman Chemical Company filed a current report to furnish its financial results for the fourth quarter of 2025. The company states that it publicly released these results on January 29, 2026, and has attached the full earnings press release as an exhibit.
The earnings release is provided as Exhibit 99.01 and is incorporated by reference, but is designated as “furnished” rather than “filed” under securities law, which affects how it is treated for certain legal liabilities and future regulatory filings.
Eastman Chemical Company reported an equity award to executive officer Stephen G. Crawford, EVP, Technology Projects. On 01/02/2026, he received 34,193 restricted stock units (RSUs), each representing a contingent right to receive one share of Eastman Chemical common stock. These RSUs were reported as derivative securities beneficially owned directly.
The RSUs carry a conversion price of $0 and are scheduled to vest and pay out in unrestricted shares of common stock on February 2, 2027, subject to Mr. Crawford’s continued employment. After this grant, he beneficially owns 34,193 derivative securities in the form of RSUs tied to Eastman Chemical common stock.
BlackRock, Inc. has filed an amended Schedule 13G reporting a significant passive ownership position in Eastman Chemical Co common stock. As of the event date of 11/30/2025, BlackRock reports beneficial ownership of 13,598,433 shares, representing 11.9% of Eastman Chemical’s outstanding common stock. BlackRock has sole voting power over 13,254,753 of these shares and sole dispositive power over all 13,598,433 shares, with no shared voting or dispositive power.
The filing is made on a passive basis, with BlackRock certifying the shares were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of Eastman Chemical. The filing notes that one underlying holder, iShares Core S&P Small-Cap ETF, has an interest in more than five percent of Eastman Chemical’s outstanding common stock.